VEGFA and diabetic macular edema: Indeed, the possible neurotoxicity of anti-VEGF was implied in clinical trials of nAMD and diabetic macular edema (DME), in which high-dose ranibizumab inversely reduced long-term visual acuity despite improving vascular symptoms [61,62].